Q. You recently wrote that testosterone does not increase the risks for heart attacks. But you overlooked the real risk of testosterone therapy: cancer! I survived advanced prostate cancer seven years ...

The phase 2b study is an open-label trial that will enroll 40 men with advanced prostate cancer who are appropriate candidates for ADT. Participants will receive an initial loading dose of teverelix ...

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...

These results suggest that oxybutynin may offer a practical and effective option for managing ADT-associated hot flashes in ...

This article was reviewed by Felix Gussone, MD. Key Takeaways: In the U.S., testosterone is a controlled substance, so you’ll ...